Aimmune, maker of peanut allergy treatment, will be acquired by Nestle

Aimmune, maker of peanut allergy treatment, will be acquired by Nestle

STAT Plus: Aimmune Therapeutics, maker of peanut allergy treatment, will be acquired by Nestle

By ADAM FEUERSTEIN

PATRICK SISON/AP

Aimmune believed Palforzia could deliver annual sales exceeding $1 billion, but the coronavirus shutdowns severely impacted its launch.

READ MORE